<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422022000300060</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Módulo 3 Poblaciones especiales: Paciente geriátrico, nefrópata y con enfermedad hepática crónica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quesada Chaves]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coto Yglesias]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Volio]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Martínez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Peraza]]></surname>
<given-names><![CDATA[H. K.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Montero]]></surname>
<given-names><![CDATA[J. G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Obando Vega]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz Vargas]]></surname>
<given-names><![CDATA[F. J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ulate Retana]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruíz Salazar]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Spencer Meléndez]]></surname>
<given-names><![CDATA[D.C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zúñiga Kondrashova]]></surname>
<given-names><![CDATA[M.D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zúñiga Solano]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital San Vicente de Paul  ]]></institution>
<addr-line><![CDATA[Heredia ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,aff2  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital San Vicente de Paúl  ]]></institution>
<addr-line><![CDATA[Heredia ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,CCSS  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af5">
<institution><![CDATA[,CCSS  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af6">
<institution><![CDATA[,aff6  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af7">
<institution><![CDATA[,Hospital Los Chiles  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Caja Costarricense de Seguro Social  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af9">
<institution><![CDATA[,aff9  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="A10">
<institution><![CDATA[,aff10  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A11">
<institution><![CDATA[,CCSS  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A12">
<institution><![CDATA[,Hospital San Rafael de Alajuela CCSS ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A13">
<institution><![CDATA[,Clínica Marcial Fallas Díaz  ]]></institution>
<addr-line><![CDATA[Desamparados ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>07</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>07</month>
<year>2022</year>
</pub-date>
<volume>24</volume>
<fpage>60</fpage>
<lpage>85</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422022000300060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422022000300060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422022000300060&amp;lng=en&amp;nrm=iso"></self-uri></article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laiteerapong]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[ES.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes in older adults. In: National Institute of Diabetes and digestive and Kidney Diseases, ed.]]></article-title>
<source><![CDATA[Diabetes in America]]></source>
<year>2018</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Center for Disease Control Prevention. U.S. Department of Health and Human Services</collab>
<source><![CDATA[National Diabetes Statistics Report 2020. Estimates of Diabetes and Its Burden in the United States]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[12. Older Adults: Standards of Medical Care in Diabetes-2021.]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<page-range>S168-79</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirkman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Briscoe]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes in Older Adults]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2650-64</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young-Hyman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[De Groot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hill-Briggs]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Hood]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Peyrot]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychosocial care for people with diabetes: A position statement of the American diabetes association]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2016</year>
<volume>39</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2126-40</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blazer]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Yaffe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Liverman]]></surname>
<given-names><![CDATA[CT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognitive Aging: Progress in Understanding and Opportunities for Action]]></article-title>
<source><![CDATA[National Academies Press]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sudore]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Karter]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptom burden of adults with type 2 diabetes across the disease course: diabetes &amp; aging study.]]></article-title>
<source><![CDATA[J Gen Intern Med]]></source>
<year>2012</year>
<volume>27</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1674-1681.</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laiteerapong]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Karter]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlates of Quality of Life in Older Adults With Diabetes]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2011</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1749-1753.</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sesti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Antonelli Incalzi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bonora]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of diabetes in older adults.]]></article-title>
<source><![CDATA[Nutr Metab Cardiovasc Dis.]]></source>
<year>2018</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>206-218.</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cukierman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[JD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cognitive decline and dementia in diabetes - Systematic overview of prospective observational studies]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2005</year>
<volume>48</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2460-2469.</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Knopman]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Przybelski]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of type 2 diabetes with brain atrophy and cognitive impairment.]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2014</year>
<volume>82</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1132-1141.</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Von Strauss]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Qiu]]></surname>
<given-names><![CDATA[CX]]></given-names>
</name>
<name>
<surname><![CDATA[Winblad]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fratiglioni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uncontrolled diabetes increases the risk of Alzheimer&#8217;s disease: A populationbased cohort study]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2009</year>
<volume>52</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1031-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yaffe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Falvey]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes, Glucose Control, and 9-Year Cognitive Decline Among Older Adults Without Dementia]]></article-title>
<source><![CDATA[Arch Neurol.]]></source>
<year>2012</year>
<volume>69</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1170-1175.</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rawlings]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Sharrett]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[ALC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes in midlife and cognitive change over 20 years: A cohort study.]]></article-title>
<source><![CDATA[Ann Intern Med.]]></source>
<year>2014</year>
<volume>161</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>785-793.</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Launer]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-label substudy]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2011</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>969-977.</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial.]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2017</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-80.</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scarpini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Galimberti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ghezzi]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disease-modifying drugs in Alzheimer's disease.]]></article-title>
<source><![CDATA[Drug Des Devel Ther.]]></source>
<year>2013</year>
<volume>7</volume>
<numero>1471</numero>
<issue>1471</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Craft]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Montine]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment.]]></article-title>
<source><![CDATA[Arch Neurol.]]></source>
<year>2012</year>
<volume>69</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-38.</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freiherr]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hallschmid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intranasal insulin as a treatment for alzheimer&#8217;s disease: A review of basic research and clinical evidence]]></article-title>
<source><![CDATA[CNS Drugs.]]></source>
<year>2013</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>505-514.</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alagiakrishnan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sankaralingam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Ghosh]]></given-names>
</name>
<name>
<surname><![CDATA[Mereu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Senior]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antidiabetic Drugs and Their Potential Role in Treating Mild Cognitive Impairment and Alzheimer&#8217;s Disease]]></article-title>
<source><![CDATA[Discov Med.]]></source>
<year>2013</year>
<volume>16</volume>
<numero>90</numero>
<issue>90</issue>
<page-range>277-86</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="">
<collab>National I on A</collab>
<source><![CDATA[Assessing Cognitive Impairment in Older Patients | National Institute on Aging.]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="">
<source><![CDATA[Alzheimer´s Association. Cognitive Assessment | Alzheimer&#8217;s Association.]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Folstein]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Folstein]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[McHugh]]></surname>
<given-names><![CDATA[PR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Mini-mental state&#8221;: A practical method for grading the cognitive state of patients for the clinician.]]></article-title>
<source><![CDATA[J Psychiatr Res.]]></source>
<year>1975</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>189-198.</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Scanlan]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ganguli]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mini-Cog as a Screen for Dementia: Validation in a Population-Based Sample]]></article-title>
<source><![CDATA[J Am Geriatr Soc.]]></source>
<year>2003</year>
<volume>51</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1451-1454.</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nasreddine]]></surname>
<given-names><![CDATA[ZS]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Bédirian]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment.]]></article-title>
<source><![CDATA[J Am Geriatr Soc.]]></source>
<year>2005</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>695-699.</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[CF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression among older adults with diabetes mellitus]]></article-title>
<source><![CDATA[Clin Geriatr Med.]]></source>
<year>2015</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>117-137.</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[American]]></surname>
<given-names><![CDATA[GS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines Abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update]]></article-title>
<source><![CDATA[J Am Geriatr Soc.]]></source>
<year>2013</year>
<volume>61</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2020-2026.</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>Psychological Association A.</collab>
<source><![CDATA[APA | Guidelines for the Evaluation of Dementia and Age-Related Cognitive Change I APA TASK FORCE ON THE EVALUATION OF DEMENTIA AND AGE-RELATED COGNITIVE CHANGE APPROVED BY APA COUNCIL OF REPRESENTATIVES FEBRUARY 2021]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Sharrett]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Selvin]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk Factors for Severe Hypoglycemia in Black and White Adults With Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2017</year>
<volume>40</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1661-1667.</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feinkohl]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Aung]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: The edinburgh type 2 diabetes study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>507-515.</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Rawlings]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study.]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2018</year>
<volume>61</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1956-1965.</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Punthakee]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Launer]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes: Post hoc epidemiologic analysis of the ACCORD trial.]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2012</year>
<volume>35</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>787-793.</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whitmer]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Karter]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yaffe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Quesenberry]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Selby J]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus.]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2009</year>
<volume>301</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1565-1572.</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Byington]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Intensive Glucose Lowering in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2545-59</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duckworth]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Abraira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Moritz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2009</year>
<volume>360</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>129-139.</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selvin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brancati]]></surname>
<given-names><![CDATA[FL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Burden and Treatment of Diabetes in Elderly Individuals in the U.S.]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2006</year>
<volume>29</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2415-2419.</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bandeen-Roche]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Seplaki]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frailty in Older Adults: A Nationally Representative Profile in the United States.]]></article-title>
<source><![CDATA[Journals Gerontol - Ser A Biol Sci Med Sci]]></source>
<year>2015</year>
<volume>70</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1427-1434.</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalyani]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[Q-L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperglycemia and Incidence of Frailty and Lower Extremity Mobility Limitations in Older Women]]></article-title>
<source><![CDATA[J Am Geriatr Soc]]></source>
<year>2012</year>
<volume>60</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1701-1707.</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pilla]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenborn]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Maruthur]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[ES.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Approaches to Risk Assessment Among Older Patients With Diabetes]]></article-title>
<source><![CDATA[Curr Diab Rep.]]></source>
<year>2019</year>
<volume>19</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffith]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Prentice]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Mohr]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Conlin]]></surname>
<given-names><![CDATA[PR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting 5-and 10-year mortality risk in older adults with diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2020</year>
<volume>43</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sgaravatti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bermúdez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Barboza]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Velocidad de marcha del adulto mayor funcionalmente saludable]]></article-title>
<source><![CDATA[An la Fac Med]]></source>
<year>2018</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>93-101.</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinclair]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dunning]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Colagiuri]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Global Guideline for Managing Older People with Type 2 Diabetes.]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beckett]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of hypertension in patients 80 years of age or older]]></article-title>
<source><![CDATA[Minerva Med]]></source>
<year>2008</year>
<volume>358</volume>
<page-range>1887-98</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Boer]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Bangalore]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Benetos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes and Hypertension: A Position Statement by the American Diabetes Association]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1273-84</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Goodpaster]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Strotmeyer]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes: The Health, Aging, and Body Composition Study]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2006</year>
<volume>55</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1813-1818.</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Goodpaster]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Strotmeyer]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes: The Health, Aging, and Body Composition Study]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2007</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1507-1512.</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Foreyt]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes]]></article-title>
<source><![CDATA[Curr Atheroscler Rep]]></source>
<year>2014</year>
<volume>16</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>457</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rejeski]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aging and physical function in type 2 diabetes: 8 Years of an intensive lifestyle intervention.]]></article-title>
<source><![CDATA[Journals Gerontol - Ser A Biol Sci Med Sci.]]></source>
<year>2015</year>
<volume>70</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>345-353.</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espeland]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rejeski]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[West]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensive Weight Loss Intervention in Older Individuals: Results from the Action for Health in Diabetes Type 2 Diabetes Mellitus Trial]]></article-title>
<source><![CDATA[J Am Geriatr Soc.]]></source>
<year>2013</year>
<volume>61</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>912-22</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noale]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Veronese]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cavallo Perin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment.]]></article-title>
<source><![CDATA[Acta Diabetol]]></source>
<year>2016</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>323-330.</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Lipska]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mayo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[DK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin in patientswith type 2 diabetes and kidney disease a systematic review.]]></article-title>
<source><![CDATA[JAMA - J Am Med Assoc]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2020</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>255-323.</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<numero>9131</numero>
<issue>9131</issue>
<page-range>854-865.</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz A]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrosius]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of TZD use and discontinuation on fracture rates in ACCORD bone study]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2015</year>
<volume>100</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>4059-4066.</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Billington]]></surname>
<given-names><![CDATA[EO]]></given-names>
</name>
<name>
<surname><![CDATA[Grey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bolland]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2015</year>
<volume>58</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2238-2246.</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Douros]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[OHY]]></given-names>
</name>
<name>
<surname><![CDATA[Filion]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Suissa]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2017</year>
<volume>40</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1506-1513.</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samuel]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults]]></article-title>
<source><![CDATA[J Am Geriatr Soc]]></source>
<year>2015</year>
<volume>63</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2227-2246.</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stafford]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Elahi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meneilly]]></surname>
<given-names><![CDATA[GS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EFFECT OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR SITAGLIPTIN IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS]]></article-title>
<source><![CDATA[J Am Geriatr Soc.]]></source>
<year>2011</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1148-1149.</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Umezawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kubota]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study]]></article-title>
<source><![CDATA[BMC Endocr Disord.]]></source>
<year>2015</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8.</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Nauck]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hehnke]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Woerle]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[von Eynatten]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[RR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.]]></article-title>
<source><![CDATA[Diabetes, Obes Metab.]]></source>
<year>2015</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>868-877.</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Huisman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Von Eynatten]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Woerle]]></surname>
<given-names><![CDATA[HJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: A randomised, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>382</volume>
<numero>9902</numero>
<issue>9902</issue>
<page-range>1413-1423.</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karyekar]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Ravichandran]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Frederich]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged &#8805; 65 years) with inadequately controlled type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Clin Interv Aging.]]></source>
<year>2013</year>
<volume>8</volume>
<page-range>419-30</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halimi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raccah]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schweizer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dejager]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.]]></article-title>
<source><![CDATA[Curr Med Res Opin.]]></source>
<year>2010</year>
<volume>26</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1647-1656.</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Josse]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Majumdar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.]]></article-title>
<source><![CDATA[Diabetes, Obes Metab.]]></source>
<year>2017</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>78-86</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mamza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marlin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chokkalingam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Idris]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2016</year>
<volume>116</volume>
<page-range>288-98</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Alessio]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Fradkin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2018</year>
<volume>41</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2669-701</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Teoh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2015</year>
<volume>38</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1145-53</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Bethel]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>232-242.</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Heller]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>369</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1327-1335.</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marso]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Brown-Frandsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.]]></article-title>
<source><![CDATA[]]></source>
<year>2016</year>
<volume>375.</volume>
<page-range>311-22</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Franek]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial]]></article-title>
<source><![CDATA[Ann Intern Med.]]></source>
<year>2019</year>
<volume>170</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>423</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Janmohamed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10157</numero>
<issue>10157</issue>
<page-range>1519-29</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinclair]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paolisso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bourdel-Marchasson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gadsby]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez Mañas]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary]]></article-title>
<source><![CDATA[Diabetes Metab]]></source>
<year>2011</year>
<volume>37</volume>
<page-range>S27-S38.</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Candeias]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Correia]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.]]></article-title>
<source><![CDATA[Biochim Biophys Acta - Mol Basis Dis.]]></source>
<year>2013</year>
<volume>1832</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>527-541.</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hunter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hölscher]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.]]></article-title>
<source><![CDATA[BMC Neurosci]]></source>
<year>2012</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6.</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seufert]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.]]></article-title>
<source><![CDATA[Diabetes, Metab Syndr Obes Targets Ther.]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>543</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Bandyopadhyay]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hajra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Biswas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2016</year>
<volume>212</volume>
<page-range>29-36.</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2015</year>
<volume>373</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2117-2128.</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JHY]]></given-names>
</name>
<name>
<surname><![CDATA[Foote]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Blomster]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2016</year>
<volume>4</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>411-419.</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Stenlöf]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Usiskin]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.]]></article-title>
<source><![CDATA[Hosp Pract]]></source>
<year>1995</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>72-84</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chilton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tikkanen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes, Obes Metab.]]></source>
<year>2015</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1180-1193.</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sonesson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Johnsson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gause-Nilsson]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis]]></article-title>
<source><![CDATA[Cardiovasc Diabetol.]]></source>
<year>2016</year>
<volume>15</volume>
<numero>37</numero>
<issue>37</issue>
</nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fioretto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mansfield]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Ptaszynska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yshai]]></surname>
<given-names><![CDATA[Yavin &#8226;]]></given-names>
</name>
<name>
<surname><![CDATA[Johnsson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2016</year>
<volume>33</volume>
<page-range>511-22</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2019</year>
<volume>380</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-357.</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cavender]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[AZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>249-259.</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rådholm]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Figtree]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>138</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>458-468.</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wanner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Lachin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>323-34</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jardine]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2295-2306.</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>644-657.</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90.</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Tsimihodimos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Liamis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Elisaf]]></surname>
<given-names><![CDATA[MS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitorsinduced electrolyte abnormalities: An analysis of the associated mechanisms]]></article-title>
<source><![CDATA[Diabetes Metab Syndr Clin Res Rev.]]></source>
<year>2018</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-63.</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors and urinary tract infections.]]></article-title>
<source><![CDATA[Nat Rev Endocrinol.]]></source>
<year>2019</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>687-688.</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yokoyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nagao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Honjo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes]]></article-title>
<source><![CDATA[J Diabetes Investig]]></source>
<year>2019</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>439-45</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unnikrishnan]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Kalra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Purandare]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Vasnawala]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genital infections with sodium glucose cotransporter-2 inhibitors: Occurrence and management in patients with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Indian J Endocrinol Metab]]></source>
<year>2018</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>837-42</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefits/Risks of Sodium-Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes |Enhanced Reader]]></article-title>
<source><![CDATA[Women&#8217;s Heal.]]></source>
<year>2016</year>
<volume>3</volume>
<page-range>379-88</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<collab>The Royal Australian College of General Practitioners and Diabetes Australia</collab>
<article-title xml:lang=""><![CDATA[Management of Type 2 Diabetes: A Handbook for General Practice.]]></article-title>
<source><![CDATA[The Royal Australian College of General Practitioners and Diabetes Australia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B97">
<label>97.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunning]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Palliative and end of life care of people with diabetes: Issues, challenges and strategies.]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2018</year>
<volume>143</volume>
<page-range>454-63</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kutner]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Blatchford]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Intern Med.]]></source>
<year>2015</year>
<volume>175</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>691-700.</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diabetes]]></surname>
<given-names><![CDATA[UK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[End of Life Diabetes Care.]]></article-title>
<source><![CDATA[Clinical Care Recommendations]]></source>
<year>2018</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angelo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruchalski]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sproge]]></surname>
<given-names><![CDATA[BJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An approach to diabetes mellitus in hospice and palliative medicine.]]></article-title>
<source><![CDATA[J Palliat Med]]></source>
<year>2011</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83-7</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Omura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Toyoshima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Araki]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nutrition Management in Older Adults with Diabetes: A Review on the Importance of Shifting Prevention Strategies from Metabolic Syndrome to Frailty]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2020</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3367</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo-García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise benefits on Alzheimer&#8217;s disease: State-of-the-science]]></article-title>
<source><![CDATA[Ageing Res Rev.]]></source>
<year>2020</year>
<volume>62</volume>
<page-range>doi:10.1016/j.arr.2020.101108</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lukács]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of aerobic and anaerobic exercises on glycemic control in type 1 diabetic youths.]]></article-title>
<source><![CDATA[World J Diabetes]]></source>
<year>2015</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>534-42</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fried]]></surname>
</name>
<name>
<surname><![CDATA[Tangen]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Walston]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frailty in older adults: Evidence for a phenotype]]></article-title>
<source><![CDATA[Journals Gerontol - Ser A Biol Sci Med Sci.]]></source>
<year>2001</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>146-156.</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walston]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McBurnie]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frailty and Activation of the Inflammation and Coagulation Systems With and Without Clinical Comorbidities&lt;subtitle&gt;Results From the Cardiovascular Health Study]]></article-title>
<source><![CDATA[Arch Intern Med.]]></source>
<year>2002</year>
<volume>162</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2333-41</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Woodward]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab.]]></source>
<year>2020</year>
<volume>105</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>152-62</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Houston]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Neiberg]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physical function following a long-term lifestyle intervention among middle aged and older adultswith type 2 diabetes: The look AHEAD study]]></article-title>
<source><![CDATA[Journals Gerontol - Ser A Biol Sci Med Sci]]></source>
<year>2018</year>
<volume>73</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1552-9</page-range></nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volkert]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cederholm]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESPEN guideline on clinical nutrition and hydration in geriatrics]]></article-title>
<source><![CDATA[Clin Nutr.]]></source>
<year>2019</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-47</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshimura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kamada]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relations of nutritional intake to age, sex and body mass index in Japanese elderly patients with type2 diabetes: The Japanese Elderly Diabetes Intervention Trial.]]></article-title>
<source><![CDATA[Geriatr Gerontol Int.]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>29-40.</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>110</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isanejad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sirola]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rikkonen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Higher protein intake is associated with a lower likelihood of frailty among older women, Kuopio OSTPRE-Fracture Prevention Study]]></article-title>
<source><![CDATA[Eur J Nutr.]]></source>
<year>2020</year>
<volume>59</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1181-1189.</page-range></nlm-citation>
</ref>
<ref id="B111">
<label>111</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otsuka]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tange]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tomida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dietary Factors Associated with the Development of Physical Frailty in Community-Dwelling Older Adults]]></article-title>
<source><![CDATA[J Nutr Heal Aging]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89-95.</page-range></nlm-citation>
</ref>
<ref id="B112">
<label>112</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[J-E]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[H-S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protein supplementation improves muscle mass and physical performance in undernourished prefrail and frail elderly subjects: a randomized, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Am J Clin Nutr.]]></source>
<year>2018</year>
<volume>108</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1026-1033.</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>113</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of Vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimer&#8217;s disease: A potential therapeutic target?]]></article-title>
<source><![CDATA[J Chem Neuroanat]]></source>
<year>2017</year>
<volume>85</volume>
<page-range>36-42.</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>114</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balboa-Castillo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Struijk]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Garcia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Banegas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[OdríguezArtalejo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guallar-Castillon]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low vitamin intake is associated with risk of frailty in older adults]]></article-title>
<source><![CDATA[Age Ageing]]></source>
<year>2018</year>
<volume>47</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>872-879.</page-range></nlm-citation>
</ref>
<ref id="B115">
<label>115</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jayanama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Theou]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Godin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rockwood]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of fatty acid consumption with frailty and mortality among middle-aged and older adults]]></article-title>
<source><![CDATA[Nutrition]]></source>
<year>2020</year>
<volume>70</volume>
<numero>110610</numero>
<issue>110610</issue>
</nlm-citation>
</ref>
<ref id="B116">
<label>116</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-22.</page-range></nlm-citation>
</ref>
<ref id="B117">
<label>117</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonaccio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Castelnuovo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costanzo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mediterranean diet and mortality in the elderly: A prospective cohort study and a meta-analysis.]]></article-title>
<source><![CDATA[Br J Nutr.]]></source>
<year>2018</year>
<volume>120</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>841-54</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>118</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kojima]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Avgerinou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Iliffe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Walters]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to Mediterranean Diet Reduces Incident Frailty Risk: Systematic Review and MetaAnalysis]]></article-title>
<source><![CDATA[J Am Geriatr Soc.]]></source>
<year>2018</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>783-788.</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>119</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pizato]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[da Mata]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Figueiredo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[MG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mediterranean Diet and Musculoskeletal-Functional Outcomes in Community-Dwelling Older People: A Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[J Nutr Heal Aging.]]></source>
<year>2018</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>655-63</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>120</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tepper]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alter Sivashensky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rivkah Shahar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Geva]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[CukiermanYaffe]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between Mediterranean diet and the risk of falls and physical function indices in older type 2 diabetic people varies by age]]></article-title>
<source><![CDATA[Nutrients.]]></source>
<year>2018</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>767</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>121</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fard]]></surname>
<given-names><![CDATA[NRP]]></given-names>
</name>
<name>
<surname><![CDATA[Amirabdollahian]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Haghighatdoost]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dietary patterns and frailty: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Nutr Rev.]]></source>
<year>2019</year>
<volume>77</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>498-513.</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>122</label><nlm-citation citation-type="journal">
<collab>World Health Organization</collab>
<article-title xml:lang=""><![CDATA[Risk Reduction Of Cognitive Decline And Dementia: WHO Guidelines.]]></article-title>
<source><![CDATA[World Health Organization]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B123">
<label>123.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chopra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bansal]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bansal]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of nephropathy and its parameters in patients with diabetes mellitus- A prospective study in a Central Indian Population]]></article-title>
<source><![CDATA[J Adv Med Dent Scie Res.]]></source>
<year>2021</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-39.</page-range></nlm-citation>
</ref>
<ref id="B124">
<label>124</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential Pathogenesis of Advanced Diabetic Nephropathy based on Bioinformatic Analysis.]]></article-title>
<source><![CDATA[Proc Anticancer Res.]]></source>
<year>2021</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>125</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saxena]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Deol]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Goyal]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of risk factors for diabetic nephropathy among newly diagnosed Type 2 diabetic subjects: A pilot study.]]></article-title>
<source><![CDATA[Eur J Mol Clin Med.]]></source>
<year>2020</year>
<volume>7</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>5543-5547.</page-range></nlm-citation>
</ref>
<ref id="B126">
<label>126</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currie]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berni]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Berni]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B127">
<label>127.</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Microvascular complications and foot care: Standards of medical care in diabetes-2021]]></article-title>
<source><![CDATA[Diabetes Care.]]></source>
<year>2021</year>
<volume>44</volume>
<page-range>S151-67</page-range></nlm-citation>
</ref>
<ref id="B128">
<label>128</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Imam]]></surname>
<given-names><![CDATA[TH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes in metformin use in chronic kidney disease]]></article-title>
<source><![CDATA[Clin Kidney J.]]></source>
<year>2017</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>301-304.</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>129</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnouts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bolignano]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nistor]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucose-lowering drugs in patients with chronic kidney disease: A narrative review on pharmacokinetic properties.]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2014</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1284-1300.</page-range></nlm-citation>
</ref>
<ref id="B130">
<label>130</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Stefánsson B]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Correa-Rotter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin in Patients with Chronic Kidney Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1436-1446.</page-range></nlm-citation>
</ref>
<ref id="B131">
<label>131</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheen]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Metab]]></source>
<year>2019</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>110-121.</page-range></nlm-citation>
</ref>
<ref id="B132">
<label>132</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Promrat]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wands]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases.]]></article-title>
<source><![CDATA[World J Hepatol]]></source>
<year>2020</year>
<volume>12</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>533-57</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>133</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Vecchio Blanco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gentile]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marmo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carbone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Coltorti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alterations of glucose metabolism in chronic liver disease]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>1990</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-36</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>134</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grancini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Trombetta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lunati]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contribution of &#946;-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease]]></article-title>
<source><![CDATA[J Hepatol.]]></source>
<year>2015</year>
<volume>63</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1484-90</page-range></nlm-citation>
</ref>
<ref id="B135">
<label>135</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Delegue]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pessione]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and outcome of patients with cirrhosis and refractory ascites.]]></article-title>
<source><![CDATA[Liver Int.]]></source>
<year>2004</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>457-464.</page-range></nlm-citation>
</ref>
<ref id="B136">
<label>136</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quintana]]></surname>
<given-names><![CDATA[JOJ]]></given-names>
</name>
<name>
<surname><![CDATA[García-Compean]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[JAG]]></given-names>
</name>
</person-group>
<source><![CDATA[The Impact of Diabetes Mellitus in Mortality of Patients with Compensated Liver Cirrhosis-a Prospective Study.]]></source>
<year>2011</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B137">
<label>137.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuji]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tsujii]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral Glucose Tolerance Test Predicts Prognosis of Patients with Liver Cirrhosis.]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2006</year>
<volume>101</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70-75.</page-range></nlm-citation>
</ref>
<ref id="B138">
<label>138</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marceau]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Biron]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hould]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver pathology and the metabolic syndrome X in severe obesity]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab.]]></source>
<year>1999</year>
<volume>84</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1513-1517.</page-range></nlm-citation>
</ref>
<ref id="B139">
<label>139</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 diabetes mellitus and the risk of hepatitis C virus infection: A systematic review.]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2013</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2981</page-range></nlm-citation>
</ref>
<ref id="B140">
<label>140</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Ratziu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[El-Serag]]></surname>
<given-names><![CDATA[HB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis.]]></article-title>
<source><![CDATA[J Hepatol.]]></source>
<year>2008</year>
<volume>49</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>831-844.</page-range></nlm-citation>
</ref>
<ref id="B141">
<label>141</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Younossi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Adeyemi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stepanova]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2016</year>
<volume>150</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1599-1608.</page-range></nlm-citation>
</ref>
<ref id="B142">
<label>142</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS. FICHA TÉCNICA Metformina</collab>
<source><![CDATA[]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B143">
<label>143</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[Ficha Tecnica de Glipizida.]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B144">
<label>144</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[Ficha Técnica Glimepirida.]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B145">
<label>145.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS. FICHA TÉCNICA GLICAZIDA</collab>
<source><![CDATA[]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B146">
<label>146</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[Ficha Técnica Glibenclamida.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B147">
<label>147.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[Ficha Técnica Pioglitazona.]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B148">
<label>148.</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[FICHA TÉCNICA Acarbosa.]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B149">
<label>149</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[FICHA TÉCNICA VILDAGLIPTINA.]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B150">
<label>150</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[FICHA TÉCNICA SITAGLIPTINA.]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B151">
<label>151</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[FICHA TÉCNICA SAXAGLIPTINA]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B152">
<label>152</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[Ficha Técnica Linagliptina]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B153">
<label>153</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha Técnica Alogliptina.]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B154">
<label>154</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[FICHA TÉCNICA EXENATIDA]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B155">
<label>155</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[FICHA TÉCNICA LIRAGLUTIDA]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B156">
<label>156</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[FICHA TÉCNICA LIXISENATIDA]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B157">
<label>157</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS</collab>
<source><![CDATA[FICHA TÉCNICA Semaglutida]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B158">
<label>158</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios.</collab>
<source><![CDATA[FICHA TÉCNICA CANAGLIFLOZINA.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B159">
<label>159</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[Ficha Técnica Dapagliflozina.]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B160">
<label>160</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS. FICHA TÉCNICA EMPAGLIFOZINA</collab>
<source><![CDATA[]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B161">
<label>161</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios - AEMPS.</collab>
<source><![CDATA[FICHA TÉCNICA Ertugliflozina.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
